Category News

Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic

Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic The WHO Director-General has the pleasure of transmitting the Report of the fifteenth meeting of the International Health Regulations (2005) (IHR) Emergency Committee regarding the…

Read MoreStatement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic

Farxiga extended in the US to reduce risk of cardiovascular death and hospitalisation for heart failure to a broader range of patients

Farxiga extended in the US to reduce risk of cardiovascular death and hospitalisation for heart failure to a broader range of patients AstraZeneca’s Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death, hospitalisation for heart…

Read MoreFarxiga extended in the US to reduce risk of cardiovascular death and hospitalisation for heart failure to a broader range of patients

Bristol Myers Squibb’s TRANSCEND FL and TRANSCEND NHL 001 Studies of Breyanzi (lisocabtagene maraleucel)in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma Meet Primary Endpoint of Overall Response Rate

Bristol Myers Squibb’s TRANSCEND FL and TRANSCEND NHL 001 Studies of Breyanzi (lisocabtagene maraleucel)in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma Meet Primary Endpoint of Overall Response Rate  Bristol Myers Squibb (NYSE: BMY) today announced positive topline results from…

Read MoreBristol Myers Squibb’s TRANSCEND FL and TRANSCEND NHL 001 Studies of Breyanzi (lisocabtagene maraleucel)in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma Meet Primary Endpoint of Overall Response Rate

Public consultation of experts to join the Guideline Development Group (GDG) for Defeating Meningitis by 2030 Roadmap: Meningitis diagnosis, treatment and care guidelines

Public consultation of experts to join the Guideline Development Group (GDG) for Defeating Meningitis by 2030 Roadmap: Meningitis diagnosis, treatment and care guidelines Despite successful efforts to control meningitis in several regions of the world, it continues to be a…

Read MorePublic consultation of experts to join the Guideline Development Group (GDG) for Defeating Meningitis by 2030 Roadmap: Meningitis diagnosis, treatment and care guidelines

Update on FDA Advisory Committee Vote on LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer

Update on FDA Advisory Committee Vote on LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer RAHWAY, N.J.–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the…

Read MoreUpdate on FDA Advisory Committee Vote on LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer

Lilly’s tripeptide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2

Lilly’s tripeptide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2 Eli Lilly and Company (NYSE: LLY) announced today that tirzepatide (10 mg and 15 mg) achieved superior weight loss compared to…

Read MoreLilly’s tripeptide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2

Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Provention Bio, Inc.

Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Provention Bio, Inc.  Sanofi announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), applicable to Sanofi’s proposed acquisition of Provention Bio, Inc.…

Read MoreHart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Provention Bio, Inc.

REGENERON AND ALNYLAM REPORT POSITIVE INTERIM PHASE 1 

REGENERON AND ALNYLAM REPORT POSITIVE INTERIM PHASE 1 CLINICAL DATA ON ALN-APP, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR ALZHEIMER’S DISEASE AND CEREBRAL AMYLOID ANGIOPATHY Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today positive interim results from the ongoing single ascending dose…

Read MoreREGENERON AND ALNYLAM REPORT POSITIVE INTERIM PHASE 1